A matched cohort study was designed to test the efficacy of polyclonal rabbit antiserum specific for human T cells (Thymoglobulin), administered in vivo on days 1-5 (2 mg/kg/day) before T cell-replete unrelated donor marrow transplantation. Thymoglobulin was given to 52 leukemic patients at Huddinge Hospital. Control patients matched for diagnosis, disease stage, age and treated with a similar regimen, apart from the omission of Thymoglobulin, were selected in Seattle during the same period (n ‫؍‬ 104). All received conditioning with cyclophosphamide and TBI. In the study group all patients received 10 Gy single dose TBI, while the controls were given 12-14.4 Gy fractionated TBI. GVHD prophylaxis was cyclosporine and methotrexate. Patients were treated for grade I acute GVHD in the study group, and for grade II GVHD in the control group. Multivariable analyses were adjusted for patient and donor age and CMV serology, HLA matching, donor gender and marrow cell dose. Non-relapse mortality was lower in the study patients (hazard ratio ‫؍‬ 0.30, 95% CI 0.12-0.75, P value ‫؍‬ 0.005). The 5-year cumulative incidence of non-relapse mortality was 19% in the study cohort, and 35% in the control cohort. Overall mortality was also lower in study patients (hazard ratio 0.51, 95% CI 0.27-0.97, P value ‫؍‬ 0.03). No significant difference in the risk of relapse was seen (P ‫؍‬ 0.63). This suggests that Thymoglobulin during conditioning may reduce non-relapse mortality after unrelated donor marrow transplantation.
Allogeneic marrow transplantation is the treatment of choice for many hematological malignancies, severe aplastic anemia, inborn errors of metabolism and immunodeficiency syndromes. 1, 2 Major obstacles to success include graft-versus-host disease (GVHD), infections, toxic effects of treatment, and recurrence of disease. 3, 4 While only onethird of the patients have an HLA-identical sibling, the use of unrelated donors has increased over the last 15 years. [5] [6] [7] [8] [9] However, marrow transplantation from unrelated donors confers an increased risk of complications compared to HLA-identical sibling donors, presumably because of undetected HLA mismatches. [10] [11] [12] [13] Unrelated recipients have a higher frequency of graft failure, severe GVHD, infections and delayed immune reconstitution. 14 To reduce the risks of graft failure and GVHD, many transplant centers, including ours, have included the use of anti-thymocyte globulin (ATG) before transplant. 15 However, it remains unknown whether ATG has any effect on survival. Here in a matched cohort study, we compare 52 patients who received ATG before unrelated donor transplantation to 104 patients who did not.
Patients and methods

Patients
The study cohort consisted of 52 patients with leukemia transplanted at Huddinge University Hospital, who had been given Thymoglobulin  (IMTIX, Sangstat, Lyon, France) during the conditioning before transplantation. A matched cohort of control patients, who did not receive T cell-specific antibodies in the conditioning regimen or as part of GVHD prophylaxis, was selected among those transplanted at the Fred Hutchinson Cancer Research Center (FHCRC) during the same period (1993) (1994) (1995) (1996) (1997) (1998) . Two control patients were matched to each study patient. The control patients were selected to match exactly by disease and disease stage, and if possible by age (within 5 years), HLA match and recipient CMV serology. One hundred and two of the 104 control patients matched the study patients by least four of the five factors. The remaining two control patients matched by three of the five factors. Patients with AML or ALL in CR1 were admitted for transplantation due Bone Marrow Transplantation to high risk criteria like chromosomal aberrations, high leukocyte counts at diagnosis or difficulty in achieving a remission. Patient and donor characteristics of the two groups are shown in Table 1 .
Donors
HLA matching was based on typing for HLA-A and -B antigens by serological methods, and typing of DRB1 alleles by DNA amplification with sequence-specific primers or DNA hybridization by sequence-specific oligonucleotide probes. 16, 17 All donors and recipient pairs were compatible for broad HLA-A, -B and -DR antigens. However, four (8%) pairs in the study group and 15 (14%) in the control group were mismatched for HLA-A, -B, or -DR sub-types. Furthermore, 36% of the pairs in the study group and 27% in the control group were mismatched for HLA-C. For HLA-DQ, the corresponding figures were 16% and 10%. The stem cell source was T cell-replete bone marrow in all cases. In the study group 16 (31%) of the donors came from the NMDP (USA) registry, 13 (25%) from the Swedish Tobias registry and 23 (44%) from different central European registries. In the control group 77 (74%) of the donors came from the NMDP registry, 22 (21%) from various European registries, two from Canada, two from Australia and one from Japan. 
Conditioning
The patients received cyclophosphamide (Cy), 60 mg/kg/day ϫ 2 consecutive days. The study cohort received 10 Gy total body irradiation (TBI) in a single dose, with the lungs shielded to receive no more than 9 Gy, as reported elsewhere. 18 The control cohort received 12-14.4 Gy TBI in 6-14 fractions over 3-6 days, as reported elsewhere. 19, 20 
GVHD prophylaxis
All patients received a short course of methotrexate (MTX) combined with cyclosporine A (CsA). MTX was given i.v. on day 1 in a dose of 15 mg/m 2 and thereafter 10 mg/m 2 on days 3, 6 and 11. CsA was given i.v. from day Ϫ1 in a dose of 3-7.5 mg/kg/day in Huddinge and 3-5 mg/kg/day in Seattle, with the higher dose given to small children. The dose was later adjusted to maintain therapeutic blood levels. When tolerated, oral cyclosporine was given instead in a dose of 12.5 mg/kg/day. If no signs of GVHD were present after 2-6 months, CsA was slowly tapered and discontinued. Details of the regimens have been published elsewhere.
21,22
ATG
All patients in the study cohort received Thymoglobulin  in a dose of 2.0 mg/kg/day from day Ϫ5 to day Ϫ1 before transplantation. 15 No patient in the control cohort received anti-T cell antibodies as part of conditioning or GVHD prophylaxis.
Acute GVHD
Acute GVHD was diagnosed according to standard criteria. 23 Acute GVHD was treated with 6-methylprednisolone i.v., beginning at 2 mg/kg/day or an equivalent dose of oral prednisone, which was tapered after an initial response. However, patients were treated for grade I acute GVHD at Huddinge Hospital, 24 and for grade II GVHD at FHCRC. 25 
Study endpoints
In this study the primary endpoint was non-relapse mortality, and the secondary endpoints overall survival, relapse and disease-free survival (DFS). DFS was defined as survival with no signs of recurrent malignancy.
Statistics
Cumulative incidence estimates were used to measure unadjusted non-relapse mortality and relapse. 26 The unadjusted probabilities of survival, and DFS were calculated with the method of Kaplan-Meier. 27 The Cox regression model was used for multivariable analyses which were stratified on the matched triplets (one study patient and two control patients). 28 All analyses were adjusted for patient age (р18, Ͼ18), donor age (р35, Ͼ35), HLA-matching, patient and donor CMV serology, donor sex and marrow cell dose (р3.84, Ͼ3.84). The effect of study was evaluated by the likelihood ratio test comparing models with and without this variable. In analyses of the competing risks of relapse and non-relapse mortality, patients were censored at the time of the competing event, if that occurred first. All P values are two-sided. All analyses were made with the SAS (SAS, Cary, NC, USA) statistical software.
Results
Characteristics of study and control cohorts
Cases and controls were matched by disease and stage of the disease. There were no differences between the two cohorts in patient and donor age and sex distribution, CMV serology before transplant, HLA matching, and nucleated marrow cell dose (Table 1) . Acute grade II GVHD developed in six (12%) study patients, and 57 (55%) controls. Acute grade III-IV GVHD occurred in none of the study patients, but in 31 (30%) controls. In the study group 44/52 (85%) received treatment for GVHD, compared to 90/104 (87%) in the control group. Two patients in both groups suffered from graft failure. No post-transplant lymphoproliferative disease developed among the Thymoglobulin-treated patients.
Bone Marrow Transplantation Years after transplantation Figure 1 Cumulative incidence of non-relapse mortality in patients treated with or without Thymoglobulin during conditioning before transplantation.
Non-relapse mortality
In the multivariable analysis, the non-relapse mortality was significantly lower in the study group (hazard ratio 0.30, 95% CI 0.12-0.75, P ϭ 0.005), after adjusting for patient and donor age, HLA matching, patient and donor CMV pretransplant serology, donor sex and marrow cell dose. The cumulative incidence of non-relapse mortality at 100 days was 6% in the study cohort, compared to 21% in the control cohort, and at 1 year, the figures were 15% and 28%, respectively ( Figure 1) . Outcome variables are shown in Table 2 .
Survival
In the adjusted multivariate analysis, overall mortality was also lower in the study cohort (hazard ratio 0.5, CI 0.27-0.97, P ϭ 0.03). The probability of survival at 5 years was 50% in the study cohort, compared to 39% in the controls (Figure 2 ). Causes of death are displayed in Table 3 .
Relapse
The risk of relapse did not differ between the two cohorts in the multivariable analysis (hazard ratio 1.29, CI 0.46-3.60, P ϭ 0.63). The 5-year probabilities of relapse were 41% in the study cohort and 27% in the controls ( Figure  3 ). In patients with CML in CP, the relapse probability was significantly higher in the study group (60% at 5 years) compared to the controls (18%, P ϭ 0.04, Figure 4 ). For ARDS ϭ adult respiratory distress syndrome; IP(S) ϭ idiopathic pneumonia (syndrome); GVHD ϭ graft-versus-host disease. patients with acute leukemia in CR relapse probability was similar in the two groups.
Disease-free survival
In the adjusted multivariable analysis, the disease-free survival rate was better in the study cohort (hazard ratio 0.51, CI 0.28-0.95, P ϭ 0.03). The probability of DFS at 6 months was 79% in the study cohort and 60% in the controls, the difference between the two curves in the early period being entirely due to the higher non-relapse mortality rate in the control cohort. Because of the occurrence of late relapses in the study cohort, however, the separation between the two groups diminished, and the probabilities of DFS at 5 years were 40% and 38% in the study and control cohorts, respectively ( Figure 5 ). In the study group, eight of nine patients with CML who relapsed were treated with donor lymphocyte infusions (DLI) at a median dose of 2.0 ϫ 10 8 kg (range 0.2-6.3). Five of these patients entered a new remission, two only temporarily (1 and 10 months) while three still are disease-free 3-6 years after DLI.
Discussion
Several studies have reported the use of ATG in various formulations and doses, 29, 30 but this matched cohort study is the first to compare directly the results in patients conditioned with or without ATG before unrelated marrow transplantation. We used Thymoglobulin  because it had been found to be more effective than other anti-T cell antibody preparations in preventing GVHD at Huddinge, 15 and rejection of organ transplants in two controlled clinical trials. 31, 32 In the present matched cohort study, Thymoglobulin was associated with a significant decrease in nonrelapse mortality after unrelated donor marrow transplantation for leukemia. Our results are consistent with the findings of the International Marrow Unrelated Search and Transplant study, where additional immunosuppression with T cell-specific antibodies or total lymphoid irradiation before unrelated donor marrow grafting was associated with improved survival. 14 Patient age, diagnosis and stage of disease, CMV serology, marrow cell dose, and year of transplantation, characteristics shown to be important for outcome, were wellmatched in the study and control cohorts. Median patient age was 5.5 years lower in the study group, but this difference was not statistically significant (P ϭ 0.20). Furthermore, patient age was not significant in any of the multivariable analyses. However, conditioning of the recipient and GVHD prophylaxis were similar, but not identical. The study cohort was conditioned with 10 Gy single-dose TBI, while the control cohort was given12-14.4 Gy fractionated TBI. A previous randomized trial had found that recipient conditioning with a regimen of 14.85 Gy fractionated TBI was associated with a lower incidence of interstitial pneumonia and lower overall mortality than 10 Gy. 33 Furthermore, the use of 13.2 Gy in adults or 14.4 Gy in children up to the age of 18 was associated with about the same survival rate among patients transplanted using HLA-A or -B mismatched donors. 20 The study cohort was given an initial CsA dose of 3-7.5 mg/kg/day, and the control cohort one of 3-5 mg/kg/day. Two previous trials comparing initial CsA doses of 1.5 vs 3.0 mg/kg/day, or 1.0 vs 5.0 mg/kg/day found no differences in the non-relapse mortality rates. 34, 35 Therefore, differences in TBI dose fractionation or initial CsA dose were probably not the reason for the lower non-relapse mortality in the study cohort.
Administration of Thymoglobulin before transplantation can eliminate most recipient T cells and reduce the risk of graft rejection. 29 Timing of the administration seems to have a large effect on the risk of GVHD after transplantation. If given long before transplantation, anti-T cell antibodies are rapidly removed and do not persist after the marrow infusion. 15 If given just before transplantation, however, functional antibodies remain in the recipient blood for weeks after the marrow infusion and, presumably, deplete donor T cells in vivo, thereby decreasing the risk of GVHD. 15 In line with this concept, we have found that the risk of moderate-to-severe acute GVHD was lower in the cohort treated with Thymoglobulin. We believe that protection from GVHD reduced the non-relapse mortality.
The effect of ATG on the peak GVHD score could not be reliably assessed in this study because the GVHD severity thresholds for initiating therapy were grade I in Huddinge, and grade II in Seattle. This was a confounding variable because early treatment or even prophylaxis with glucocorticoids is assumed to reduce the probability of GVHD progressing to a moderate or severe stage. In two randomized trials, however, the early use of glucocorticoids increased the risk of untoward side-effects and infections, thereby eliBone Marrow Transplantation minating the benefits of preventing GVHD on GVHD-associated mortality. 36, 37 These data support our view that the use of Thymoglobulin rather than early treatment with glucocorticoids in the study cohort caused a reduction in nonrelapse mortality.
The balance between recipient and donor T cells is important for engraftment. The risk of rejection may be lowered by reducing the number of recipient T cells. On the other hand, reduction of T cells in the graft may increase the risk of rejection. Treatment with Thymoglobulin is better than ex vivo T cell depletion because it induces not only depletion of donor T cells, thereby preventing GVHD, but also of recipient T cells, thus reducing the risk of graft rejection.
The incidence of relapse seemed to be higher among patients treated with Thymoglobulin than in controls (41% vs 27% at 5 years). The difference in relapse between the two treatment cohorts was primarily among patients with CML-CP. Donor T cells are responsible for GVHD and graft-versus-leukemia effects. 38, 39 Ex vivo T cell depletion of the marrow graft is associated with a lower incidence of GVHD, and an increased risk of leukemia relapse, mainly in patients with CML. 40, 41 In a previous study from Huddinge University Hospital, comparing three types of anti-T cell antibodies, we found the lowest incidence of acute GVHD and the highest incidence of relapse among patients with CML-CP receiving Thymoglobulin. 15 Therefore, we assume that treatment with Thymoglobulin reduces the incidence of GVHD and increases the risk of relapse among those with CML-CP by depleting T cells in vivo.
To achieve a favorable balance between decreased GVHD and leukemic relapse in patients with CML-CP, 41, 42 it is important to define more exactly an appropriate dose of Thymoglobulin. Perhaps, a Thymoglobulin dose as high as 10 mg/kg is not necessary to control GVHD, and a lower dose might be associated with a lower risk of relapse. At Huddinge, we have started a Thymoglobulin dose de-escalating study to find the lowest dose of Thymoglobulin associated with a tolerable incidence of acute GVHD and a low relapse rate. On the basis of the present results more controlled studies of Thymoglobulin in unrelated donor marrow transplantation are needed for diseases other than CML-CP.
